Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 08, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 17:11 ET
|
Translate Bio, Inc.
-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA...
TRANSLATE BIO ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TBIO and Encourages Investors to Contact the Firm
August 03, 2021 11:37 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
August 03, 2021 01:00 ET
|
Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 07, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
June 22, 2021 01:00 ET
|
Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 09, 2021 16:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
June 07, 2021 07:30 ET
|
Translate Bio, Inc.
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to...
Translate Bio to Participate in Upcoming Investor Conferences
May 24, 2021 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference
May 18, 2021 10:00 ET
|
Translate Bio, Inc.
– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into...